The clinical significance of heterogeneity in asthma

Completed

• Conditions: Asthma; Respiratory - Asthma

• Registration Number: ACTRN12605000317695
• Lead Sponsor: Central Sydney Area Health Service

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2005-09-06
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 47

Inclusion Criteria

Doctor-diagnosed asthma, with symptoms in the last 12 months.

Exclusion Criteria

Current smoking (in the last 6 months)* > 10 pack year history of smoking* Any other lung disease* Oral prednisone use in the last 4 weeks* Respiratory tract infection in the last 4 weeks.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Ventilation heterogeneity[Measured at baseline, and then at 1, 2 and 3 months during treatment.]

Secondary Outcome Measures

Name	Time	Method
Airway hyper-responsiveness[Measured at baseline, and then at 1, 2 and 3 months during treatment.];Exhaled nitric oxide[Measured at baseline, and then at 1, 2 and 3 months during treatment.];Lung function (spirometry and body plethysmography)[Measured at baseline, and then at 1, 2 and 3 months during treatment.];Respiratory system resistance[Measured at baseline, and then at 1, 2 and 3 months during treatment.];Cough sounds and respiratory symptoms. [Measured at baseline, and then at 1, 2 and 3 months during treatment.]